Chugai Seiyaku KK

4519

Equity

ISIN JP3519400000 / Valor 761611

Tokyo Stock Exchange (2024-09-18)

JPY 6,754.00-1.65%

Chugai Seiyaku KK
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Chugai Seiyaku KK is a research-based pharmaceutical company that specializes in the development, production, and marketing of prescription medicines, with a strong focus on biopharmaceuticals and molecular targeted therapies. The company emphasizes the importance of safety and regulatory compliance, having established an independent Drug Safety Division to ensure the secure and appropriate use of its products globally. Chugai's Quality & Regulatory Compliance Unit oversees the adherence to pharmaceutical regulations and maintains the integrity of its quality management system through rigorous audits and a global IT system. The company prioritizes high-value R&D projects and actively secures intellectual property rights, including lifecycle patents and innovative drug discovery technologies. Chugai collaborates closely with the Roche Group for global co-development, aiming to bring innovative medicines to market efficiently and effectively.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Decline

In the second quarter of FY2024, Chugai Seiyaku KK reported a revenue of ¥552.9 billion, marking a 4.6% decrease year on year. This decline was primarily attributed to a reduction in sales, despite an increase in other revenue streams.

Operating Profit Increase

Chugai Seiyaku KK's operating profit for the same period saw a significant increase, reaching ¥258.2 billion. This represents a 22.4% rise compared to the previous year, showcasing improved operational efficiency and cost management.

Net Income Growth

The net income for Chugai Seiyaku KK in FY2024 Q2 was ¥186.3 billion, an 18.9% increase year on year. This growth in net income reflects the company's strong financial performance despite the challenges in revenue.

Core Operating Profit

Chugai Seiyaku KK's core operating profit for the first half of FY2024 was ¥262.8 billion, which is a 13.3% increase year on year. This improvement was driven by a favorable product mix and increased efficiency in operations.

FY2024 Outlook

For the full fiscal year 2024, Chugai Seiyaku KK projects revenues to decrease by 3.7% to ¥1,070.0 billion. However, core operating profit is expected to rise by 2.1% to ¥460.0 billion, and core net income is anticipated to grow by 0.6% to ¥335.5 billion, indicating a positive outlook despite revenue challenges.

Summarized from source with an LLMView Source

Key figures

49.2%1Y

60.9%3Y

162%5Y

Performance

33.3%1Y

28.9%3Y

29.7%5Y

Volatility